Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219441
Title: Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode
Author: Jordà Baleri, Teresa
Garriga, Marina
Mezquida Mateos, Gisela
Cuesta, Manuel J.
Martínez-Arán, Anabel, 1971-
García Rizo, Clemente
Lobo, Antonio
González-Pinto, Ana
Díaz Caneja, Covadonga M.
Roldán, Alexandra
Vieta i Pascual, Eduard, 1963-
Baeza, Inmaculada, 1970-
Trabsa, Amira
Montalvo, Itziar
Tortorella, Alfonso
Menculini, Giulia
Verdolini, Norma
Ramos Quiroga, Josep Antoni
Sánchez Torres, Ana M.
Bernardo Arroyo, Miquel
Amoretti Guadall, Silvia
PEPs Group
Keywords: Psicosi
Prolactina
Diferències entre sexes
Símptomes
Antipsicòtics
Psychoses
Prolactin
Sex differences
Symptoms
Antipsychotic drugs
Issue Date: Nov-2024
Publisher: Elsevier Ltd.
Abstract: Aim: To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP). Methods: We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex. Results: Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline. Conclusions: Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes.
Note: Versió postprint del document publicat a: https://doi.org/10.1016/j.psyneuen.2024.107112
It is part of: Psychoneuroendocrinology, 2024, vol. 169
URI: https://hdl.handle.net/2445/219441
Related resource: https://doi.org/10.1016/j.psyneuen.2024.107112
ISSN: 0306-4530
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut de Neurociències (UBNeuro))

Files in This Item:
File Description SizeFormat 
874351.pdf2.09 MBAdobe PDFView/Open    Request a copy


Embargat   Document embargat fins el 31-10-2025


This item is licensed under a Creative Commons License Creative Commons